
Study investigator David Berg explains why volume overload shouldn't decide which hospitalized patients get an SGLT2 inhibitor.
Bill Sullivan, executive director of SPAARx, describes how his organization's definition of "specialty pharmacy" compares with other entities' definitions.
Bill Sullivan, executive director of SPAARx, describes how his organization's definition of "specialty pharmacy" compares with other entities' definitions.
Read